AcuityBio

About:

AcuityBio is a commercialize novel polymer drug delivery technologies.

Description:

AcuityBio was founded by Mark Grinstaff, Ph.D., Alain Hanover, M.S., Jesse Wolinsky, Ph.D., and John 'Jay' Schwartz, Ph.D. in late 2009 to commercialize novel polymer drug delivery technologies to treat various types early stage, soft tissue cancers. AcuityBio's lead product candidate aimed at preventing the recurrence of non-small cell lung cancer is based on a synthetic polymer technology invented by co-founders Professor Mark Grinstaff, Ph.D. and Jesse Wolinsky, Ph.D. at Boston University (BU), Departments of Biomedical Engineering and Chemistry. AcuityBio is a privately-held company based in the Greater Boston area.

Total Funding Amount:

$2.45M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Newton, Massachusetts, United States

Founded Date:

2009-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2017-11-13

IPO Status:

Private

Industries: